Title:
USE OF JWA POLYPEPTIDE IN PREPARATION OF DRUG FOR RESISTING NEOVASCULAR OCULAR DISEASE
Document Type and Number:
WIPO Patent Application WO/2023/240958
Kind Code:
A1
Abstract:
The present invention relates to a use of a JWA polypeptide in preparation of a drug for resisting a neovascular ocular disease. The amino acid sequence of the polypeptide is shown as I or II: I: FPGSDRF-Z; II: X-FPGSDRF-Z, wherein an amino acid S is subjected to phosphorylation modification, and X and Z respectively are amino acids or amino acid sequences; X is selected from one of F, (R)9, (R)9-F, 6-aminocaproic acid, 6-aminocaproic acid-F, 6-aminocaproic acid-(R)9, and 6-aminocaproic acid-(R)9-F; and Z is selected from one of (G)n-RGD and A-(G)n-RGD, n is an integer greater than or equal to 0, and the value range of n is 0-10. The polypeptide can be used as a candidate molecule for treating or preventing the neovascularization ocular disease, is used for preparing the drug for treating or preventing the neovascular ocular disease, and has a good use prospect.
Inventors:
ZHOU JIANWEI (CN)
XIE ZHAN (CN)
XIE ZHAN (CN)
Application Number:
PCT/CN2022/138732
Publication Date:
December 21, 2023
Filing Date:
December 13, 2022
Export Citation:
Assignee:
ZHOU JIANWEI (CN)
International Classes:
C07K7/06; A61K38/08; A61P9/10; A61P27/06; A61P37/02; C07K1/107
Foreign References:
| CN114940702A | 2022-08-26 | |||
| CN103239710A | 2013-08-14 |
Other References:
VAN HOVE INGE; HU TJING-TJING; BEETS KAREN; VAN BERGEN TINE; ETIENNE ISABELLE; STITT ALAN W.; VERMASSEN ELKE; FEYEN JEAN H.M.: "Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, vol. 85, 26 March 2021 (2021-03-26), GB , XP086862823, ISSN: 1350-9462, DOI: 10.1016/j.preteyeres.2021.100966
CUI JIAHUA, SHU CHUANJUN, XU JIN, CHEN DONGYIN, LI JIN, DING KUN, CHEN MINJUAN, LI AIPING, HE JINGDONG, SHU YONGQIAN, YANG LIUQING: "JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin αvβ3 signaling", THERANOSTICS, IVYSPRING INTERNATIONAL PUBLISHER, AU, vol. 10, no. 18, 1 January 2020 (2020-01-01), AU , pages 8036 - 8050, XP093117557, ISSN: 1838-7640, DOI: 10.7150/thno.45843
ZHI-WEN JIANG, LI WEN-LEI; WANG YI-BO; LI JIAN; XU HAN-MEI: "Development of Integrin αVβ3-Related Diseases and Target Drugs", PHARMACEUTICAL BIOTECHNOLOGY, vol. 28, no. 4, 15 August 2021 (2021-08-15), pages 429 - 435, XP093117559
CUI JIAHUA, SHU CHUANJUN, XU JIN, CHEN DONGYIN, LI JIN, DING KUN, CHEN MINJUAN, LI AIPING, HE JINGDONG, SHU YONGQIAN, YANG LIUQING: "JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin αvβ3 signaling", THERANOSTICS, IVYSPRING INTERNATIONAL PUBLISHER, AU, vol. 10, no. 18, 1 January 2020 (2020-01-01), AU , pages 8036 - 8050, XP093117557, ISSN: 1838-7640, DOI: 10.7150/thno.45843
ZHI-WEN JIANG, LI WEN-LEI; WANG YI-BO; LI JIAN; XU HAN-MEI: "Development of Integrin αVβ3-Related Diseases and Target Drugs", PHARMACEUTICAL BIOTECHNOLOGY, vol. 28, no. 4, 15 August 2021 (2021-08-15), pages 429 - 435, XP093117559
Attorney, Agent or Firm:
NANJING IPLEADER INTELLECTUAL PROPERTY AGENCY FIRM (CN)
Download PDF: